Robert W. Baird Issues Positive Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price

Mirum Pharmaceuticals (NASDAQ:MIRM) had its target price lifted by Robert W. Baird from $50.00 to $55.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s target price points to a potential upside of 8.87% from the company’s previous close.

MIRM has been the topic of several other research reports. HC Wainwright restated a “buy” rating and set a $66.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Citigroup raised their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $57.60.

Mirum Pharmaceuticals Price Performance

Shares of MIRM stock opened at $50.52 on Thursday. The stock’s fifty day moving average is $46.72 and its 200-day moving average is $43.32. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The stock has a market capitalization of $2.43 billion, a PE ratio of -25.01 and a beta of 0.96. Mirum Pharmaceuticals has a 52 week low of $23.14 and a 52 week high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.22). The business had revenue of $99.41 million for the quarter, compared to the consensus estimate of $96.64 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. Equities research analysts expect that Mirum Pharmaceuticals will post -1.43 EPS for the current fiscal year.

Insider Transactions at Mirum Pharmaceuticals

In other news, COO Peter Radovich sold 2,627 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $48.22, for a total transaction of $126,673.94. Following the completion of the transaction, the chief operating officer now directly owns 26,961 shares in the company, valued at approximately $1,300,059.42. The trade was a 8.88 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Christopher Peetz sold 7,489 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total transaction of $320,678.98. Following the completion of the sale, the chief executive officer now directly owns 119,359 shares of the company’s stock, valued at $5,110,952.38. The trade was a 5.90 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 40,915 shares of company stock worth $1,897,920. 22.87% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several hedge funds have recently bought and sold shares of MIRM. Creative Planning acquired a new stake in Mirum Pharmaceuticals in the third quarter worth $249,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Mirum Pharmaceuticals by 22.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after acquiring an additional 318 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of Mirum Pharmaceuticals by 65.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,176 shares of the company’s stock worth $358,000 after acquiring an additional 3,639 shares during the period. Rice Hall James & Associates LLC raised its holdings in shares of Mirum Pharmaceuticals by 5.7% during the third quarter. Rice Hall James & Associates LLC now owns 242,711 shares of the company’s stock worth $9,466,000 after acquiring an additional 12,981 shares during the period. Finally, GSA Capital Partners LLP raised its holdings in shares of Mirum Pharmaceuticals by 791.7% during the third quarter. GSA Capital Partners LLP now owns 57,985 shares of the company’s stock worth $2,261,000 after acquiring an additional 51,482 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.